Waylis Therapeutics
As of the edition of 20 October 2026, Waylis Therapeutics runs 10 drugs, 10 of them marketed; it is on route A at 0 targets and on route B at 3 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 10 |
| Total | 10 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Busulfan | none listed | 0 |
| Hydroxyurea | none listed | 1 |
| Rabeprazole | none listed | 1 |
| Carvedilol | none listed | 3 |
| Thioguanine | none listed | 0 |
| Dutasteride | none listed | 6 |
| Omega-3-acid ethyl esters | none listed | 0 |
| Eszopiclone | none listed | 0 |
| Diazepam | none listed | 1 |
| Chlorambucil | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 3 targets.
All 3 rows on route A or B
In the product3 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 3 targets where Waylis Therapeutics needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.